Genetic ablation or antibody blockade of FGL1 signaling inhibited liver metastasis and tumor growth by promoting CD8+ T and NK cell functions, suggesting that FGL1 is an immunotherapy target for liver cancer (Figures 4–6 and 8). The gene discussed is CD8A; the disease is liver cancer.